UNSPSC 51293703: Nomifensine maleate

This classification denotes an antidepressant agent with the molecular formula C16H18N2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 76S8CUH5MR, chemically known as 1,2,3,4-tetrahydro-2-methyl-4-phenyl-8-isoquino* but more generally known as nomifensine maleate, which bears US NIH Compound Identifier 4528. European Medicines Agency schedules Nomifensine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14663MIG.

Most nations, for tariff and trade purposes, schedule nomifensine maleate under HS 29334990 and SITC 51575. As of Q4 2014, NOMIFENSINE MALEATE remains US FDA's Preferred Term for this commodity. Nomifensine maleate bears US NLM identifiers UMLS ID C0877847 and NCI Concept Code C73808. SMILES: CN1CC2C(CCCC2N)C(C1)C3CCCCC3.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51293703 Nomifensine maleate is a Commodity code that nominally designates a specific pharmaceutical ingredient, but recent state and local opportunities show little purchasing activity directly aligned with the code's scope. The three recent opportunities posted under or near this code actually target naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products distributed through established wholesaler networks, and direct-to-manufacturer prescription program capabilities—none of which involve nomifensine maleate specifically. State and local procurement offices issuing under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances spanning multiple states. The issuing bodies and notice types vary: Seminole County, Florida posted an IFB for naloxone procurement; the Texas Health and Human Services Commission issued an RFI exploring therapeutic pharmacy direct-contracting models; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) published an RFP for generic pharmaceutical and OTC product supply agreements affecting participating states including Oregon.

Activity under this code reflects fragmented pharmaceutical procurement across Florida, Texas, and the MMCAP member jurisdictions, with no apparent concentration. The Seminole County IFB (IFB60459723LAS) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, and a July 26, 2023 response deadline (now closed). The Texas HHS RFI (HHS0017013), posted April 3, 2026, gathered market intelligence on direct-to-manufacturer prescription fulfillment capabilities without issuing formal award. The MMCAP RFP (S1070000015802), due March 26, 2026, established multi-award contracts for generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson) for a July 1, 2026 effective date. The code shows limited decision relevance for firms pursuing state and local contracts in nomifensine maleate itself; opportunities tagged under it actually reflect broader pharmaceutical supply and distribution procurement that does not require this specific ingredient.